Muscle atrophy is the loss of skeletal muscle tissue. Fibres shrink, the muscle gets smaller, and strength falls with it. It is a sign, not a diagnosis in its own right.
Key takeaways
- Atrophy describes muscle that has lost mass. The clinically important question is always which kind, because disuse, nerve injury, age and systemic disease all produce the same visible result through different mechanisms.
- The rate can be fast. In 63 critically ill patients, rectus femoris cross-sectional area fell by about 17.7% by day 10 of intensive care, and the loss was larger in those with multiorgan failure.
- Muscle mass reflects the balance between protein synthesis and protein breakdown. Atrophy is what happens when breakdown, driven in part by muscle-specific ubiquitin ligases, wins for long enough.
- Diagnosis is a search for the cause. History and examination come first, then imaging or DXA for muscle quantity, blood work, and electromyography or nerve conduction studies when a neurological cause is suspected.
- Reversibility depends on the cause. Disuse atrophy responds well to loading; denervation depends on whether the nerve recovers; disease-driven wasting usually needs the disease treated.
What muscle atrophy actually is
Skeletal muscle is not static tissue. Its size at any moment reflects the balance between muscle protein synthesis and muscle protein breakdown. Tip that balance toward breakdown and hold it there, and fibres lose contractile protein: the fibre thins, the muscle shrinks, and force production falls.
That is atrophy: a description of a state rather than an explanation of one. MedlinePlus lists it under signs and symptoms for exactly that reason. A clinician who sees a wasted quadriceps has learned something real, but not yet what to do about it.
One distinction trips people up. Atrophy means tissue that was there and shrank. Muscular dystrophy is a group of inherited disorders in which a genetic fault in muscle structure or repair causes progressive degeneration, and the wasting is downstream of that. The words are not interchangeable.
The main types of muscle atrophy
Grouping by mechanism is more useful than grouping by which limb looks smaller.
| Type | What drives it | Typical setting |
|---|---|---|
| Disuse atrophy | Loss of mechanical loading and reduced activity | Limb immobilisation in a cast, bed rest, prolonged hospital stay, spinal cord injury, spaceflight |
| Neurogenic atrophy | Loss of the nerve supply that drives the muscle | Peripheral nerve injury, radiculopathy, motor neuron disease, spinal muscular atrophy |
| Age-related atrophy (sarcopenia) | Cumulative age-associated muscle changes with declining strength | Adults in later life, accelerating with inactivity and illness |
| Disease-driven wasting | Systemic inflammation and catabolism from an underlying illness | Cancer, advanced heart failure, chronic kidney disease, chronic obstructive pulmonary disease |
| Drug-related myopathy | Direct catabolic effect on muscle | Prolonged systemic glucocorticoid treatment, among others |
These categories overlap constantly in practice. An older adult admitted with pneumonia can leave hospital with age-related sarcopenia, disuse atrophy from a week in bed and inflammatory wasting from the infection, all at once. That is the rule, not the exception.
What causes muscle atrophy
Behind each type sits a fairly short list of drivers.
Unloading. Muscle responds to mechanical tension. Remove it and the tissue is downregulated within days. A 2025 review of muscle disuse atrophy notes this is seen most often after limb immobilisation for injury and in spinal cord impairment, with age and poor nutrition making it worse.
Denervation. A fibre depends on its motor neuron for both activation and trophic signalling. Cut that connection and the fibre atrophies whether or not the limb is being used.
Systemic inflammation. Chronic illness shifts the body toward protein breakdown. When this is severe, disease-driven and accompanied by weight loss, clinicians call it cachexia, which is distinct from both sarcopenia and simple disuse.
Glucocorticoids. A 2025 review in Journal of Neurology describes glucocorticoid-induced myopathy as common and often underdiagnosed, marked by proximal weakness and atrophy. It is a matter for the prescribing clinician, never something to change on your own.
Undernutrition. Too little energy or protein removes the substrate for repair. Usually a compounding factor rather than the primary one.
What happens inside the fibre
Atrophying muscle upregulates a specific set of genes, the atrogenes, that accelerate degradation of contractile protein through the ubiquitin-proteasome system. The landmark work is Bodine and colleagues in Science in 2001, which identified the muscle-specific ubiquitin ligases required for skeletal muscle atrophy. That paper is why wasting is now described in terms of tagging proteins for disposal rather than muscle simply shutting down.
Synthesis falls at the same time. In critical illness both arms move at once: Puthucheary and colleagues found depressed protein synthesis early in the intensive care stay and leg protein breakdown that stayed elevated throughout.
How quickly muscle atrophy develops
Faster than most people assume, and fastest when illness and immobility combine.
Kortebein and colleagues put 11 healthy adults averaging 67 years old on 10 days of continuous bed rest with a diet meeting the recommended protein allowance. Isotonic knee extensor strength fell 13.2%, stair-climbing power 14% and maximal aerobic capacity 12%. Healthy people, well fed, for ten days.
In the intensive care unit the numbers are steeper. Puthucheary's 63 patients lost about 17.7% of rectus femoris cross-sectional area by day 10, with a much larger fall in those who reached multiorgan failure by day 7 than in those with single organ failure.
Neither study is a reason to worry about a week off training. Both are a reason to understand why hospital teams push early mobilisation.
How muscle atrophy is diagnosed
There is no single test. The work is figuring out the cause.
- History. Onset, speed, distribution, pain, sensory change, weight loss, medications, recent immobility or illness.
- Examination. Which muscles are involved and in what pattern. Symmetric proximal weakness points somewhere quite different from wasting confined to one nerve distribution. Reflexes, tone and fasciculations narrow it further.
- Strength and function testing. Grip dynamometry, chair stand tests and gait speed give repeatable numbers.
- Imaging and body composition. DXA and bioelectrical impedance estimate muscle quantity in routine care; MRI, CT and ultrasound add detail.
- Blood tests. Creatine kinase, inflammatory markers, thyroid and renal function, and others depending on the suspected cause.
- Electrodiagnostics. Electromyography and nerve conduction studies separate a nerve problem from a muscle problem.
- Muscle biopsy. Reserved for cases still unclear after the above.
Unexplained wasting, particularly with numbness, difficulty swallowing or unintentional weight loss, is a conversation for a clinician rather than a question to resolve online.
Does muscle atrophy reverse
Sometimes fully, sometimes partly, and the type determines which.
Disuse atrophy is the most recoverable form. The 2025 disuse review is direct about it: resistance training is the most effective intervention for reversing lost mass and strength, with the caveat that some patients cannot manage intensive exercise, which is why alternatives are still being researched. Recovery is usually slower than the loss was.
Neurogenic atrophy tracks the nerve. If it recovers and reinnervates the fibres, muscle can return. If it does not, the outcome differs, and in progressive neurological disease the aim shifts toward preserving function rather than restoring mass.
Disease-driven wasting generally will not resolve while the driving illness is active. Treating the underlying condition is the intervention; nutrition and exercise support it.
Age-related sarcopenia is treatable in the sense that its trajectory can be changed, and it has its own literature and its own guidelines. That is covered separately in our pages on the sarcopenia definition, sarcopenia symptoms and sarcopenia treatment.
How muscle atrophy is coded
For readers dealing with records or billing, the coding distinctions follow the clinical ones. Muscle wasting and atrophy not elsewhere classified sits at M62.5-, which needs a further character for site. Sarcopenia has its own code, M62.84.
Cachexia splits in two. Where an underlying condition is documented, that condition is coded first and the wasting is E88.A, wasting disease due to underlying condition. Cachexia with no documented underlying cause stays at R64. The two carry a mutual Excludes1 and are never reported together. Using the sarcopenia code for disease-driven wasting is inaccurate either way. Our sarcopenia ICD-10 page covers the documentation requirements.
Where myostatin fits into muscle atrophy
Myostatin, also called GDF-8, is a transforming growth factor beta family protein that acts as a negative regulator of skeletal muscle mass. McPherron, Lawler and Lee described it in Nature in 1997 after mice lacking the gene grew dramatically larger muscles.
That finding made the pathway an obvious target for wasting, and it is why this site exists. The honest position is that blocking the pathway reliably adds lean mass in trials while repeatedly failing to deliver matching functional gains, examined in our coverage of bimagrumab, apitegromab and myostatin in sarcopenia. No myostatin-pathway drug is approved for muscle atrophy or sarcopenia, and no compound sold online as a research chemical has been shown to treat it.
Frequently asked questions
Is muscle atrophy a disease?
No. It is a physical sign that muscle tissue has been lost, and it appears in many different conditions. The clinically useful question is what caused it: disuse, loss of nerve supply, ageing, an underlying illness, or a medication. Sarcopenia is one specific named condition that involves atrophy, and it has its own diagnostic criteria.
How long does it take for muscles to atrophy?
Measurable loss can occur within days when loading stops. In a study of healthy older adults, 10 days of continuous bed rest produced a 13.2% fall in knee extensor strength and a 14% fall in stair-climbing power. In critical illness the loss is faster still, with rectus femoris cross-sectional area falling around 17.7% by day 10 of intensive care.
What is the difference between muscle atrophy and muscular dystrophy?
Atrophy means muscle that has shrunk, whatever the reason. Muscular dystrophy is a group of inherited disorders in which a genetic fault in muscle structure or repair causes progressive muscle degeneration. Dystrophy causes wasting, but most wasting is not dystrophy.
Can muscle atrophy be reversed?
It depends on the cause. Disuse atrophy is the most recoverable, and current reviews identify resistance training as the most effective intervention for restoring lost mass and strength. Atrophy from nerve injury depends on whether the nerve recovers, and wasting driven by an active systemic illness generally will not resolve while that illness is untreated.
Which doctor should I see about muscle wasting?
Start with a primary care clinician, who can take the history, examine the pattern of weakness and order first-line tests. Depending on findings they may refer on to neurology, rheumatology or geriatric medicine.
Sources
- Muscle atrophy, MedlinePlus Medical Encyclopedia
- Yeo D. Muscle Disuse Atrophy. Adv Exp Med Biol 2025;1478:157-183
- Kortebein P et al. Functional impact of 10 days of bed rest in healthy older adults. J Gerontol A Biol Sci Med Sci 2008;63(10):1076-81
- Puthucheary ZA et al. Acute skeletal muscle wasting in critical illness. JAMA 2013;310(15):1591-600
- Bodine SC et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8
- Glucocorticoid-induced myopathy: a comprehensive review. J Neurol 2025;272:734
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
- ICD-10 code M62.50, muscle wasting and atrophy NEC, unspecified site (AAPC)
- ICD-10 code M62.84, sarcopenia (AAPC)
- ICD-10 code R64, cachexia (AAPC)
- ICD-10 code E88.A, wasting disease (syndrome) due to underlying condition (AAPC)
This article is for educational purposes only and is not medical advice. It does not diagnose any condition and does not recommend any treatment, dose or change to existing medication. Muscle wasting has many possible causes, some of which are serious and time-sensitive. If you have unexplained muscle loss or weakness, speak with a qualified healthcare professional.